Gilead Shares Jump 8.28% on Strong HIV Growth and $6B Buyback, $1.26B Volume Ranks 63rd in Market Activity

Gilead Sciences (GILD) surged 8.28% on August 8, 2025, with a trading volume of $1.26 billion, ranking 63rd in market activity. The stock’s performance followed the biopharma giant’s Q2 earnings report and updated guidance, which highlighted robust HIV segment growth and strategic partnerships.

The company reported adjusted earnings of $2.01 per share, exceeding expectations, with total sales of $7.08 billion. HIV product sales rose 7% year-over-year to $5.1 billion, driven by strong demand for Biktarvy and Descovy. However, Veklury sales declined 44% to $121 million, and cell therapy revenue fell 7% to $485 million amid competitive pressures. Gilead also announced a $6.0 billion stock repurchase program and raised its 2025 adjusted earnings guidance to $7.95-$8.25 per share.

A strategic collaboration with the Global Fund to distribute lenacapavir, Gilead’s twice-yearly HIV prevention drug, was outlined. The partnership aims to provide doses to two million people over three years in supported countries, though the initiative is non-profit. Analysts emphasized the potential of Yeztugo, the newly approved PrEP injection, to drive long-term growth by addressing adherence challenges in HIV prevention.

Backtesting data revealed that a strategy of purchasing the top 500 high-volume stocks and holding them for one day generated a 166.71% return from 2022 to the present, outperforming the benchmark by 137.53%. This underscores the impact of liquidity concentration in short-term trading, particularly in volatile markets.